Oryzon Genomics SA
MAD:ORY
Oryzon Genomics SA
Other
Oryzon Genomics SA
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Oryzon Genomics SA
MAD:ORY
|
Other
€4.4m
|
CAGR 3-Years
212%
|
CAGR 5-Years
80%
|
CAGR 10-Years
23%
|
|
|
Grifols SA
MAD:GRF
|
Other
-€92m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-21%
|
|
|
Pharma Mar SA
MAD:PHM
|
Other
-€955k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Oryzon Genomics SA
Glance View
Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. The company is headquartered in Cornella De Llobregat, Barcelona and currently employs 44 full-time employees. The company went IPO on 2015-12-10. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The firm also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.
See Also
What is Oryzon Genomics SA's Other?
Other
4.4m
EUR
Based on the financial report for Dec 31, 2025, Oryzon Genomics SA's Other amounts to 4.4m EUR.
What is Oryzon Genomics SA's Other growth rate?
Other CAGR 10Y
23%
Over the last year, the Other growth was 176%. The average annual Other growth rates for Oryzon Genomics SA have been 212% over the past three years , 80% over the past five years , and 23% over the past ten years .
